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LETTERS TO THE EDITOR
On Plain Language and
Going Astray
To the Editor:
Stage classification is a nomencla-
ture to describe the anatomic extent of
tumors and nothing more. It provides a
language; however, the nature of what is
described is not affected by the language
used. A “seven-cm tumor in the left upper
lobe without nodal metastases” (English)
is the same thing as a “sieben cm Tumor
im linken Oberlappen ohne Lymphkno-
tenmetastasen” (German). Similarly, a
“7-cm T2N0M0 tumor” (6th edition clas-
sification) is the same thing as a “7-cm
T3N0M0 tumor” (7th edition classifica-
tion). As long as we remember that the
stage classification is simply a nomencla-
ture to describe anatomic tumor extent, we
do not get led astray.
We use the stage classification
nomenclature as a tool in estimating
prognosis, because the anatomic tumor
extent is an important component in-
fluencing this. But there are many
other factors, such as performance
status, histology, prognostic factors,
comorbidities, and perhaps most im-
portantly, the treatment given (at least
we like to believe that it makes a
difference).
One can look at only one factor in
isolation, such as the anatomic tumor
extent, and then describe prognosis in an
overall collective of patients with a mix-
ture of other prognostic factors, comor-
bidities, and treatments given. In fact,
this approach was used as a tool in
developing the stage categories. How-
ever, recognizing the heterogeneity of
such overall collectives grouped only by
anatomic tumor extent, the staging com-
mittee wisely set the criteria for deter-
mining the classification descriptors and
groupings to be differences in prognosis
that were consistent within various sub-
populations (e.g., histologic type, geo-
graphic region) and not the prognosis of
the heterogeneous collectives as a whole.
The figures depicting the collective prog-
nosis of a stage group should not obscure
the fact that this is a somewhat abstract
measure that is not directly applicable
to a particular patient, with particular
prognostic features, undergoing a par-
ticular treatment.
Furthermore, we should not get
misled in making assumptions about the
treatment received in the stage classifi-
cation database; in fact, this is likely to
have been quite heterogeneous. In ap-
proaching individual patients in our
clinics today, we should weigh the prog-
nosis, taking into account all factors,
and the outcomes with a particular
treatment, which are available from
up-to-date clinical trials (and not from
the stage classification per se, involv-
ing patients treated between 1990 and
2000).
The fact that differences in progno-
sis were used as a tool to develop the stage
classification and that the anatomic extent
of disease (i.e., stage classification) is used
as a tool in describing prognosis or to
describe the patients who received a par-
ticular treatment in a study does not mean
that stage classification defines the prog-
nosis or the treatment for each patient
falling within a stage cohort. I worry that
the editorial “The 7th TNM Staging
System and Lung Cancer Treatment
Choices”1 does not make this distinction
clearly enough and allows us to continue
to fall prey to this mistake. If we view
stage classification only as a nomenclature
to describe anatomic tumor extent, we do
not get led astray.
Frank C. Detterbeck, MD
Yale University School of Medicine
Thoracic Surgery
New Haven, CT
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Reply to “On Plain
Language and Going
Astray”
In Reply:
We thank Dr. Detterbeck for his
further reflections on the period of change
in tumor, node, metastasis (TNM) we are
faced with. From a theoretical point of
view, we largely agree with his comments.
Stage classification, indeed, is an an-
atomic description of malignant disease, and
it is only one element to estimate the prog-
nosis; however, it is a major one. Several
other factors—listed in Dr. Detterbeck’s
comment—indeed have the consequence
that stage defines the average prognosis of a
stage group and not of a particular patient
and that important treatment heterogeneity
may be present within a stage.
Likewise, it is true that we prefer
to base our treatment decisions on up-
to-date clinical trials, but in cases where
these decisions are stage dependent (ad-
juvant chemotherapy for a patient with
completely resected N0 non-small cell
lung cancer as a typical example), we
have to rely on the most up-to-date stag-
ing system for this decision. This is
where the difficulty and the practical
questions of many clinicians start as
illustrated in the article of Dr. Daniel
Boffa, which we commented on.1 Much
of the change from TNM6 to TNM7 in
early stages relates to the size of the
primary tumor, and most of the adjuvant
chemotherapy trials do not have detailed
data on this tumor size to compare the
treatment outcome results in TNM6 or
TNM7. Consequently, making the opti-
mal link between existing clinical trial
data and how to use these in a time
interval with a different stage classifica-
tion is difficult, until new data with more
details on tumor size and other clinical
and laboratory factors become available.
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Whether this is going astray re-
mains between theoretical pureness and
practical clinical reality, but we felt that
pointing out these reflections to clini-
cians was a useful exercise.
Johan F. Vansteenkiste, MD, PhD
Respiratory Oncology Unit (Pulmonology)
and Leuven Lung Cancer Group
University Hospital Gasthuisberg
Leuven, Belgium
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Bevacizumab
Chemotherapy for
Pulmonary Epithelioid
Hemangioendothelioma
with Severe Dyspnea
To the Editor:
In past issues of the Journal of
Thoracic Oncology,1,2 two case reports
described the controversial efficacy of
combination chemotherapy with carbopla-
tin, paclitaxel, and bevacizumab (BV) for
patients with pulmonary epithelioid he-
mangioendothelioma (PEH). Recently,
we encountered a patient with PEH and
severe dyspnea for which a similar reg-
imen was transiently effective for im-
proving symptoms. Our case report also
suggests another important issue for PEH
and treatment with BV.
A 59-year-old woman was referred
to our hospital in January 2010 with a
pulmonary tumor. She had been followed
up during the previous 10 years for mul-
tiple brain tumors, which had been slowly
glowing. A computed tomography (CT)
scan revealed a 25  35-mm pulmonary
tumor in the right upper lobe with small
ground glass opacities surrounding it (Fig-
ure 1A). An abdominal CT scan showed
multiple low-density areas that were con-
sidered to be hemangiomas on her initial
diagnosis.
A right upper lobectomy was
performed. A histopathological speci-
men showed clusters of CD31-positive
epithelioid cells that had diffusely prolif-
erated into the lung parenchyma with
marked intravascular extensions. Lymph
node metastases and satellite lesions
were also noted around the primary
tumor. These results were compatible with
PEH.
Three months later, she was read-
mitted with a dry cough and respiratory
distress. Her oxygen saturation (SpO2)
was 90% with 5 liter O2 by facemask. A
CT scan revealed diffuse ground glass
opacities in both lung fields (Figure 1B)
and slightly enlarged multiple liver tu-
mors. Because PEH recurrence was highly
suspected because of its clinical course,
combination chemotherapy with carbopla-
tin, paclitaxel, and BV (15 mg/kg) was
initiated. After two cycles of chemother-
apy, the patient showed improvements in
dyspnea and oxygen saturation (SpO2 
95% with 2 liter O2 by nasal cannula). A
CT scan also revealed apparent reduc-
tions of the diffuse ground glass opaci-
ties (Figure 1C) and the liver metastases.
However, this patient unfortunately ex-
perienced the complications of multiple
cerebral infarctions and pneumonia dur-
ing a third cycle of chemotherapy. Her
general status rapidly deteriorated, and
she died 3 months after chemotherapy
was initiated.
Our case showed a relatively ag-
gressive progression considering the
generally dormant nature of PEH. Her
brain tumors had been slowly growing,
although the exact relationship of this
brain tumor and PEH was not clear.
Increased production of vascular endo-
thelial growth factors after pulmonary
surgery might have especially contrib-
uted to the rapid progression of pulmo-
nary infiltrates, as suggested by some
reports.3,4 Because PEH is a rare tumor
of vascular origin, antiangiogenesis
therapy using BV might be a promis-
ing treatment strategy, as suggested by
our case. Our case also illustrates one
of the most serious, albeit uncommon,
adverse effects of BV: cerebral infarc-
tions. Because safety cannot be con-
firmed for these rare vascular tumors,
which commonly metastasize to the
brain, an abundance of caution should
be taken in light of this possibility.
Ayako Mizota, MD
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FIGURE 1. A, Thoracic computed tomography (CT) scan before surgery showed a pulmonary tumor in the right upper lobe.
B, CT scan before chemotherapy revealed diffuse ground glass opacities in both lung fields with pleural effusions. C, CT scan
after two cycles of chemotherapy showed improvements of the diffuse ground glass opacities and bilateral pleural effusions.
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